Opportunities and challenges of blood-based biomarkers in Alzheimer's disease

WEBINAR

Abstract

Identifying more sensitive biomarker tests for Alzheimer’s disease (AD) is an unmet medical need. It is key in the global efforts to validate disease-modifying AD therapeutics and identify appropriate recipients in clinical trials once more therapies are approved. Fluid biomarkers, especially plasma-based biomarkers, become the most attractive ones as they are non-invasive, relatively economical, and easy to obtain. Emerging blood biomarkers, including amyloid ß monomers, oligomers, tau/p-tau, neurofilament light chain, and inflammatory factors, are gathering tremendous research interest.

However, there are also challenges in developing blood biomarkers for neurological disease with specificity, precision, and reproducibility. First, biologically, there could be a tiny amount of proteins of the central nervous system entering into the peripheral bloodstream. Second, biochemically, the enriched and complex matrix of human blood strongly interferes with the detection system we use for protein identification and quantification. Third, technically, it is critical to establish a system with high reliability that is also capable of high throughput. Our expert speakers will discuss strategies in developing an ultrasensitive immunoassay to precisely measure oligomeric amyloid ß in human plasma samples.

During the webinar, the viewers will:

• Obtain insights into blood-based biomarkers used in neurological diseases such as Alzheimer’s disease.
• Discover the challenges and opportunities behind creating blood-based biomarker immunoassays.

For Research Use Only. Not For Use In Diagnostic Procedures.